Description

This vial contains a 1:1 blend of Sema (GLP-1 Agonist) and Cagri (Amylin Analogue). This combination is frequently utilized in research settings to investigate dual-hormonal pathways in energy expenditure, satiety signaling, and metabolic control.

Chemical Profile

This product is a high-purity (>99%), lyophilized (freeze-dried) powder requiring reconstitution. It is intended for laboratory handling and experimental analysis only.

• Component 1: Semaglutide (GLP-1 Receptor Agonist)

• Component 2: Cagrilintide (Long-acting Amylin Analogue)

• Total Quantity: [10mg]

• Purity: >99% (Determined by HPLC)

Quality Assurance

• HPLC Analysis: Validated >99% purity.

• Mass Spectrometry: Confirmed molecular weight and structure.

• Toxicity: Not tested for human safety.

Research Context (Literature Review)

Note: The following is for educational purposes regarding the chemical properties of these peptides and does not constitute a medical claim.

This blend allows researchers to study the co-activation of two distinct nutrient-response systems. Semaglutide targets the GLP-1 receptor to modulate insulin and glucagon. Cagrilintide is a stable analogue of Amylin, a hormone co-secreted with insulin that delays gastric emptying and induces satiety via the amylin receptors in the hindbrain.

Current laboratory trials are investigating the synergistic potential of this combination. Animal models suggest that simultaneous activation of GLP-1 and Amylin pathways results in greater weight reduction and improved glycemic control compared to the administration of either peptide alone.

Technical Specifications